SEATTLE, Sept. 16, 2021 (GLOBE NEWSWIRE) — Accolade, Inc. (NASDAQ: ACCD) today announced that it will release fiscal second quarter 2022 financial results on Thursday, October 7, 2021, after the market closes. In conjunction, the company will host a conference call to review results at 4:30 p.m. E.T. on the same day.
Conference Call Details
The conference call can be accessed by dialing 1-833-519-1281 for U.S. participants, or 1-914-800-3853 for international participants, referencing conference ID # 9547326; or via a live audio webcast that will be available online at http://ir.accolade.com.
A replay of the call will be available via webcast for on-demand listening shortly after the completion of the call, at the same web link, and will remain available for approximately 90 days.
About Accolade, Inc.
Accolade provides personalized health and benefits solutions designed to empower every person to live their healthiest life. Accolade helps millions of people and their employers navigate the complexities of the healthcare system with empathy, expertise and through exceptional service while supporting them in lowering the cost of care and improving health outcomes. Accolade blends technology-enabled health and benefits solutions, specialized support from Accolade Health Assistants® and Clinicians, and access to expert medical opinion services and virtual primary care. Accolade consistently receives consumer satisfaction ratings over 90 percent. For more information, visit Accolade on LinkedIn, Twitter, Instagram and Facebook and at accolade.com.
Investor Contact:
Todd Friedman, Investor Relations, 484-532-5200, IR@accolade.com
Asher Dewhurst, Investor Relations, 443-213-0500, accolade@westwicke.com
Media Contact:
Megan Torres, Public Relations, 206-926-8180, media@accolade.com
Source: Accolade
Halifax, Nova Scotia--(Newsfile Corp. - June 26, 2024) - Sona Nanotech Inc. (CSE: SONA) (OTCQB:…
Dallas, Georgia--(Newsfile Corp. - June 26, 2024) - Bemax Inc. (OTC Pink: BMXC), a private…
Elevate your practice and revolutionize patient care with the all-new user-friendly design and the same…
Study published in peer-reviewed journal finds BioStem’s products offer overall better treatment efficiency, and greater…
AXA is the 2nd Largest Provider of Private Medical Insurance in the UK Payer Coverage…
Ongoing Study is Investigating RenovoGem™ to treat Locally Advanced Pancreatic CancerLOS ALTOS, Calif., June 26, 2024…